英夫利昔单抗在溃疡性结肠炎中疗作用评估.docVIP

英夫利昔单抗在溃疡性结肠炎中疗作用评估 　　[摘要] 目的 评估英夫利昔单抗治疗的溃疡性结肠炎的临床疗效。方法 将随机选取该院2012年8月―2013年8月收治的80例克确诊罗恩氏病患者随机分成对照组（40例）与治疗组（40例）。对照组予综合治疗，治疗组在综合治疗基础上给予静脉输注英夫利昔单抗5 mg/kg，分别于患者用药0、2、6周及以后每隔8周用药一次，疗程6个月。观察两组治疗前后临床疗效、生化指标。结果 治疗后两组患者腹痛、腹泻、血便等临床症状不同程度缓解，内镜下病理改善，治疗组治疗总有效率为100%，高于对照组72.5%，各生化指标ESR、CRP、HB、ALB均有所改善，两组相比差异有统计学意义（P0.05）。结论 英夫利昔单抗可明显提高溃疡性结肠炎患者的临床疗效，改善生活质量。 　　[关键词] 英夫利昔单抗；溃疡性结肠炎；治疗作用；评估 　　[中图分类号] R574 [文献标识码] A [文章编号] 1674-0742（2015）09（b）-0144-02 　　[Abstract] Objective To evaluate the clinical effect of infliximab on patients of ulcerative colitis. Methods Select 80 cases of ulcerative colitis from our hospital in August 2012―August 2013， and randomly divided into control group and treatment group with 40 cases per group. The control group received combined therapy，while the treatment group was treated with intravenous infliximab 5 mg/kg besides the combined therapy， respectively in patients with medication for 0， 2， 6 weeks and every 8 weeks later in the same dose， a total of six months. Clinical curative effect and the restore of biochemical index were assessed before and after treatment. Results After treatment， clinical symptoms such as abdominal pain， diarrhea， bloody stool， ease to varying degrees， endoscopic pathological improved in two group ，the total effective rate in the treatment group was 100%，higher than the control group72.5%，the biochemical indicators ESR，CRP，HB，ALB were improved， compared two groups， the difference had statistical significance （P0.05）. Conclusion Infliximab could significantly improve the clinical treatment effect of ulcerative colitis， improve the quality of life. 　　[Key words] Infliximab； Ulcerative colitis； Therapy effect； Evaluation 　　溃疡性结肠炎（Ulcerative Colitis，简称UC）是一种病因不明的结肠、直肠慢性非特异性炎症性疾病，病变较浅，局限于肠黏膜层及黏膜下层。病变部位多位于乙状结肠和直肠，也可延伸至整个结肠。病程迁延，反复发作。该病和克罗恩氏病两者统称为炎症性肠病（Inflammatory Bowel Disease，简称IBD）。患者主要表现为腹痛、腹泻和粘液脓血便等，还可有多种肠外表现。英夫利昔单抗（IFX）为TNF-?坏タ寺】固澹?属于近年来广泛应用的新型生物制剂，研究发现，其对于中重度及激素依赖性、激素抵抗性UC有特效。该文采用英夫利昔单抗治疗2012年8月―2013年8月该院收治的UC患者80例，现